2020 연구자 정보 (21 / 991)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Seo, You Na (Seo, YN) |
Dongnam Inst Radiol & Med Sci, Res Ctr, Busan 46033, South Korea |
|
|
[JCR상위 1.8%] Ginsenoside-Rp1 inhibits radiation-induced effects in lipopolysaccharide-stimulated J774A.1 macrophages and suppresses Ched phenotypic variation in CT26 colon cancer cells | SCIE | 1.8 |
CHEMISTRY, MEDICINAL INTEGRATIVE & COMPLEMENTARY MEDICINE |
mtpark@dirams.re.kr sdkim@dirams.re.kr |
||
|
Shim, J. (Shim, J) |
제1저자 | Ewha Womans Univ, Dept Internal Med, Coll Med, Seoul, South Korea |
|
|
[JCR상위 1.8%] Clinical aspects of severe cutaneous adverse reactions caused by beta-lactam antibiotics: A study from the Korea SCAR Registry | SCIE | 1.8 |
ALLERGY IMMUNOLOGY |
||
|
Shim, Young-Ri (Shim, YR) |
Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Lab Liver Res, Daejeon 34141, South Korea |
MXL-1653-2025 Shim, Young-Ri |
0000-0002-1657-1807 Shim, Young-Ri |
[JCR상위 1.8%] Ginsenoside F2 attenuates chronic-binge ethanol-induced liver injury by increasing regulatory T cells and decreasing Th17 cells | SCIE | 1.8 |
CHEMISTRY, MEDICINAL INTEGRATIVE & COMPLEMENTARY MEDICINE |
jsbyun@knu.ac.kr wijeong@kaist.ac.kr |
||
|
Shin, D. (Shin, D) |
Daegu Fatima Hosp, Dept Orthopaed, Daegu, South Korea Daegu Fatima Hosp, Daegu, South Korea |
|
|
[JCR상위 1.8%] ENDOGENOUSLY EXPRESSED CXC CHEMOKINE RECEPTOR TYPE 7 IS INVOLVED IN INFLAMMATION OF CHONDROCYTE FROM MICE [JCR상위 1.8%] ADENOSINE AND GUANOSINE-BASED OLIGONUCLEOTIDE ATTENUATES IL-1β-MEDIATED CATABOLIC PHENOTYPES OF CHONDROCYTES AND SURGICALLY INDUCED OSTEOARTHRITIS PROGRESSION IN MICE [JCR상위 1.8%] BREAKDOWN OF THE EXTRACELLULAR MATRIX RECAPITULATES OSTEOARTHRITIC PHENOTYPES IN 3D-HYDROGEL MODEL: THE VALIDATION OF IN VITRO CELL CULTURE MODEL OF OSTEOARTHRITIS |
SCIE | 1.8 |
ORTHOPEDICS RHEUMATOLOGY |
|||
|
Son, Eunjung (Son, E) |
Korea Inst Oriental Med, KM Convergence Res Div, Daejeon, South Korea |
|
|
[JCR상위 1.8%] A novel herbal formulation consisting of red ginseng extract and Epimedium koreanum Nakai-attenuated dextran sulfate sodium-induced colitis in mice | SCIE | 1.8 |
CHEMISTRY, MEDICINAL INTEGRATIVE & COMPLEMENTARY MEDICINE |
sdkim@dirams.re.kr rheemh@knu.ac.kr |
||
|
Yang, Keungmo (Yang, K) |
Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Lab Liver Res, Daejeon 34141, South Korea |
|
|
[JCR상위 1.8%] Ginsenoside F2 attenuates chronic-binge ethanol-induced liver injury by increasing regulatory T cells and decreasing Th17 cells | SCIE | 1.8 |
CHEMISTRY, MEDICINAL INTEGRATIVE & COMPLEMENTARY MEDICINE |
jsbyun@knu.ac.kr wijeong@kaist.ac.kr |
||
|
Ye, Y. (Ye, Y) |
Ajou Univ, Dept Allergy & Clin Immunol, Sch Med, Suwon, South Korea |
|
|
[JCR상위 1.8%] Clinical aspects of severe cutaneous adverse reactions caused by beta-lactam antibiotics: A study from the Korea SCAR Registry | SCIE | 1.8 |
ALLERGY IMMUNOLOGY |
|||
|
Yi, Joo Mi (Yi, JM) |
Inje Univ, Coll Med, Dept Microbiol & Immunol, Busan, South Korea |
|
|
[JCR상위 1.8%] Ginsenoside-Rp1 inhibits radiation-induced effects in lipopolysaccharide-stimulated J774A.1 macrophages and suppresses Ched phenotypic variation in CT26 colon cancer cells | SCIE | 1.8 |
CHEMISTRY, MEDICINAL INTEGRATIVE & COMPLEMENTARY MEDICINE |
mtpark@dirams.re.kr sdkim@dirams.re.kr |
||
|
Alcindor, Thierry (Alcindor, T) |
McGill Univ, Ctr Hlth, Montreal, PQ, Canada |
|
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu | ||
|
Bang, Yung-Jue (Bang, YJ) |
Seoul Natl Univ, Coll Med, Seoul, South Korea |
J-2759-2012 Bang, Yung Jue |
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu | ||
|
Bendell, Johanna C. (Bendell, JC) |
Sarah Cannon Res Inst, Nashville, TN USA |
|
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu | ||
|
Catenacci, Daniel V. T. (Catenacci, DVT) |
제1저자 | 교신저자 | Univ Chicago, Med Ctr, Chicago, IL 60637 USA |
K-4177-2019 Catenacci, Daniel |
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu |
|
Chee, Cheng Ean (Chee, CE) |
Natl Univ Canc Inst, Singapore, Singapore |
|
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu | ||
|
Davidson-Moncada, Jan K. (Davidson-Moncada, JK) |
MacroGenics, Rockville, MD USA |
|
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu | ||
|
Enzinger, Peter C. (Enzinger, PC) |
Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA |
|
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu |
페이지 이동: